# Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

> **NCT02540161** · PHASE2 · COMPLETED · sponsor: **Annick Desjardins** · enrollment: 43 (actual)

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** Sym004 - 18 mg/kg
- **DRUG:** Sym004 - 24 mg/kg

## Key facts

- **NCT ID:** NCT02540161
- **Lead sponsor:** Annick Desjardins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2019-07-10
- **Final completion:** 2020-04-27
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02540161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02540161, "Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02540161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*